

1 **Microvascular insulin resistance associates with enhanced muscle glucose disposal in**
2 **CD36 deficiency.**

3
4 Cyndya Shibao^{1#}, Vivek S. Peche², Ian M. Williams³, Dmitri Samovski², Terri A. Pietka², Naji N.
5 Abumrad⁴, Eric Gamazon⁵, Ira J. Goldberg⁶, David Wasserman³, Nada A. Abumrad.^{2,7#}

6
7 ¹Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center,
8 Nashville TN.

9 ²Department of Medicine, Division of Nutritional Sciences and Obesity Research, Washington
10 University School of Medicine, St. Louis, MO.

11 ³Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center,
12 Nashville TN

13 ⁴Department of Surgery, Vanderbilt University Medical Center, Nashville TN.

14 ⁵Department of Medicine, Division of Genetic Medicine, Vanderbilt University, Nashville, TN

15 ⁶Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, New York
16 University Grossman School of Medicine, New York, NY

17 ⁷Department of Cell Biology & Physiology, Washington University School of Medicine, St. Louis,
18 MO.

19
20 Abbreviated title: Microvascular and muscle insulin sensitivity

21 *Key words:* Endothelial function, microvascular circulation, nitric oxide, African Americans,

22
23 *Word count: 6384 Number of tables: 2 Number of figures: 5*

24
25 *Correspondence:*

26 Cyndya Shibao, MD, M.S.C.I.
27 2220 Pierce Avenue
28 506 Robinson Research Building
29 Nashville, TN 37232
30 cyndya.shibao@vumc.org

31
32 Nada A Abumrad, PhD
33 Washington University School of Medicine
34 660 S Euclid Avenue
35 Campus Box 8031
36 St Louis, MO 63110
37 nabumrad@wustl.edu

38

39

40 **Abstract**

41 Dysfunction of endothelial insulin delivery to muscle associates with insulin resistance. CD36, a
42 fatty acid transporter and modulator of insulin signaling is abundant in endothelial cells, especially
43 in capillaries. Humans with inherited 50% reduction in CD36 expression have endothelial
44 dysfunction but whether it is associated with insulin resistance is unclear. Using
45 hyperinsulinemic/euglycemic clamps in *Cd36^{-/-}* and wildtype mice, and in 50% CD36 deficient
46 humans and matched controls we found that *Cd36^{-/-}* mice have enhanced systemic glucose
47 disposal despite unaltered transendothelial insulin transfer and reductions in microvascular
48 perfusion and blood vessel compliance. Partially CD36 deficient humans also have better glucose
49 disposal than controls with no capillary recruitment by insulin. CD36 knockdown in primary human-
50 derived microvascular cells impairs insulin action on AKT, endothelial nitric oxide synthase, and
51 nitric oxide release. Thus, insulin resistance of microvascular function in CD36 deficiency
52 paradoxically associates with increased glucose utilization, likely through a remodeling of muscle
53 gene expression.

54

55

56

57 Introduction

58 The membrane fatty acid (FA) transporter CD36 was initially identified as an insulin
59 resistance gene when CD36 sequence variants were found in the insulin-resistant spontaneously
60 hypertensive rat (SHR) a model of type 2 diabetes (T2D). Transgenic CD36 expression ameliorated
61 the defect in FA metabolism and insulin resistance of the SHR (1, 2). In humans a C/T single
62 nucleotide polymorphism (SNP rs1527479) in the CD36 promoter associates with insulin resistance
63 and T2D (3), a rare nonsense mutation (rs56381858) in a Caucasian pedigree is linked to
64 autosomal dominant T2D (4). Our genome-wide association analysis of available data from the
65 Vanderbilt BioVu patient biobank and the MAGIC Consortium show that reduced CD36 expression
66 in muscle and heart, and a SNP (rs17236824) within 1 MB of the transcription start site, associated
67 with T2D renal, ophthalmic, and neurological complications (5). In addition, a common CD36
68 haplotype is associated with T2D-linked coronary heart disease (6). The mechanisms underlying
69 the T2D-related metabolic alterations that are associated with CD36 variants remain unclear.

70 Complete CD36 deficiency has a prevalence of 0.3–11% with higher incidences in populations
71 of Asian and African descent (7, 8). CD36 coding SNP rs3211938 (G/T) is the major cause of
72 deficiency in African Americans and carriers of the minor G allele (frequency 20-25%) have 50%
73 reduction of CD36 levels (9, 10). Although deficiency is low in Caucasians (0.3%) SNPs that reduce
74 CD36 levels are common (11). Information on whether insulin sensitivity is altered in individuals
75 with partial or total CD36 deficiency is limited. Only few studies evaluated whole-body glucose
76 disposal in small cohorts of these subjects and reported conflicting results (12-14). Studies in mice
77 suggest a complex relationship between CD36 expression and insulin sensitivity. *Cd36*^{-/-} mice have
78 enhanced systemic glucose disposal, consistent with better muscle insulin sensitivity (15), however
79 this enhancement is not recapitulated by CD36 deletion in muscle (5). CD36 knockdown in cultured
80 human myotubes impairs insulin signaling, as CD36 promotes tyrosine phosphorylation of the
81 insulin receptor (IR) by Fyn kinase and enhances IR signaling to AKT (5). Surprisingly, in contrast
82 to the effect of muscle CD36 deletion, endothelial cell (EC) specific deletion enhances systemic
83 glucose disposal (16) mimicking the *Cd36*^{-/-} mouse phenotype (16). These data can be interpreted
84 to indicate that muscle glucose disposal is critically influenced by endothelial CD36. In the present
85 study we interrogated some of the underlying mechanisms and their potential relevance to humans.

86 The vasculature is the most important regulator of nutrient exchange and dysfunction of
87 microvessels can alter muscle access to circulating insulin and glucose (17, 18). Strong evidence
88 supports importance of vascular insulin action in regulating muscle glucose disposal (19, 20). For
89 example the endothelial dysfunction that associates with obesity causes a delay in insulin action to
90 increase peripheral blood flow, and correlates with reduced whole body glucose uptake (21). We

91 previously described reduced flow mediated dilation of the brachial artery and low cGMP levels in
92 subjects carrying the G-allele of CD36 coding SNP rs3211938, suggesting reduced nitric oxide (NO)
93 bioavailability (9). In this study we used metabolic insulin clamps to assess insulin sensitivity of
94 glucose disposal in *Cd36*^{-/-} mice, and in 50% CD36 deficient human carriers of the G-allele of SNP
95 rs3211938, we examined the relationship between microvascular function, transendothelial insulin
96 flux and muscle glucose uptake.

97

98 **Methods**

99 **Mice Experimental Protocols**

100 Mice studies used age-matched 3-4 months old wild-type (WT) and *Cd36*^{-/-} mice on the C57BL/6
101 background. Male and female mice were used except when indicated. Experimental protocols were
102 approved by the Animal Studies Committees of Washington University or Vanderbilt University.

103 *Vessel Compliance:* Ascending aortas and left carotid arteries (from transverse aorta to 6
104 mm up the common carotid) were dissected from euthanized WT and *Cd36*^{-/-} mice as previously
105 described (22, 23). Briefly, vessels mounted in physiological saline on a pressure arteriograph
106 (Danish Myotechnology, Copenhagen), were pressurized and longitudinally stretched to *in vivo*
107 length three times before data capture. Vessel diameter recordings used a transillumination
108 microscope connected to a camera and a computerized measurement system (Myoview, Danish
109 Myotechnology). Intravascular pressure was increased from 0 to 175 mmHg in 25-mmHg steps and
110 the vessel's outer diameter (OD) was measured at each step.

111 *Muscle insulin sensitivity in vivo:* 5 hour fasted mice were injected with intraperitoneal insulin
112 (0.75 units/kg) and tissues harvested 15 min later were quickly frozen in liquid nitrogen and kept at
113 -80°C until used for western blots as previously described (5). Antibodies used: anti-mouse CD36
114 (R&D Systems, AF1955), anti-pS473-Akt (Cell Signal Technology, 4060), anti-pT308-Akt (Cell
115 Signal Technology, 13038) and total Akt (Cell Signal Technology, 4691).

116 *Transcapillary Insulin Flux:* Intravital microscopy (IVM) of the exposed gastrocnemius was
117 used to visualize transcapillary insulin flux in WT and *Cd36*^{-/-} mice. Insulin was conjugated to Alexa
118 Fluor 647 and the probe tested to ensure purity and bioactivity comparable to unconjugated insulin
119 as previously described (24). Prior to IVM, the probe was mixed vigorously in saline, sonicated 1
120 hour, centrifuged (20 min, 13000 rpm) to remove insoluble material and microscopically inspected
121 for absence of aggregates (24). The mice were anesthetized with ketamine/xylazine/acepromazine
122 (7.9/1.6/0.2 mg/kg) via an indwelling venous catheter, placed on a heated pad. Skin of the shaved
123 lower leg was removed to expose the lateral gastrocnemius and peel off its fascia avoiding
124 perturbation of muscle fibers and blood vessels (24). For imaging the mouse was transferred to the

125 custom stage mount and its body temperature kept at 37°C through a feedback control system
126 connected to an electric blanket (Harvard Apparatus). To keep hydration and physiological stability
127 of the gastrocnemius it was continuously irrigated with bicarbonate-buffered physiological saline
128 solution (PSS); in mmol/L 132 NaCl, 4.7 KCl, 2 MgSO₄, 1.2 CaCl₂, and 18 NaHCO₃. PSS kept at
129 37°C was bubbled with 95%N₂/5%CO₂ to maintain a 7.4 pH and continuously circulated over the
130 tissue using a peristaltic pump (inflow) and a vacuum trap (outflow) (24).

131 Quality of the gastrocnemius preparation was visualized using tissue autofluorescence with
132 light from a 120W mercury arc lamp (XCite[®] 120) sent through a bandpass filter (Zeiss Filter Set
133 10; Excitation: 450-490nm, FT: 510nm, Emission: 515-565nm) onto the exposed region. To
134 visualize blood vessels the mouse was infused with 50 μg of 2 MDa rhodamine-dextran (rho-dex)
135 and the filter set switched (Zeiss Filter Set 43 HE; Excitation: 550/25nm, FT:570nm, Emission: BP
136 605/70). The field of view was selected from a capillary bed stemming from the external sural artery
137 based on 1) presence of a sufficient number of clearly visible capillaries; 2) absence of large vessels
138 in nearby area; and 3) absence of capillaries immediately adjacent to one another.

139 Intravital microscopy used an inverted Zeiss LSM 780 microscope (Zen software) with a 20X
140 0.8NA Plan-Apochromat air objective. For imaging transendothelial molecular flux (ins-647, BSA-
141 647, dextrans), rho-dex fluorescence was excited with light from a 561 nm solid-state laser and
142 detected on a multichannel PMT. Near-infrared fluorophores were excited by a helium-neon 633nm
143 laser and emitted light detected with a gallium arsenide phosphide semiconductor. For both rho-
144 dex and near-infrared fluorophores, excitation and emission light were reflected with an MBS
145 488/561/633 dichroic mirror and imaging used two-channel sequential excitation and detection to
146 avoid bleed through, in an optical section of 8 μm (+/- 4μm about the focal plane). The 8-bit intensity,
147 1024x1024 pixel images were acquired with unidirectional scanning. For each time point, a 4-“slice”
148 z-stack was acquired in each channel using a 4μm step size to avoid aliasing. Photomultiplier tube
149 settings were adjusted to maximize image dynamic range and kept constant for each experiment
150 for quantitative comparisons. The imaging region was selected, a background image (t=0) was
151 acquired then probe (rho-dex and ins-647) was injected through the venous catheter and images
152 acquired every minute at t=1-10, at 12.5 and 15 min, post probe injection (24).

153 *Hyperinsulinemic-euglycemic Insulin Clamp:* Catheters were implanted under isoflurane
154 anesthesia in the carotid artery for sampling and jugular vein for infusion a week before performing
155 clamps (25) to allow the mice to regain weight lost due to surgery. The mice were fasted for 5h
156 before the clamp and not restrained or handled during the experiments (26). [3-³H]glucose was
157 primed and continuously infused from t=-90min to t=0min (0.04 μCi/min). The insulin clamp was
158 initiated at t=0 min with a continuous insulin infusion (4 mU·kg⁻¹·min⁻¹) and a variable glucose

159 infusion rate (GIR), both maintained until $t=155$ min. Infused glucose had $0.06 \mu\text{Ci}/\mu\text{L}$ [$3\text{-}^3\text{H}$]-glucose
160 to minimize changes in plasma [$3\text{-}^3\text{H}$]-glucose specific activity. Arterial glucose was measured every
161 10 min and GIR adjusted to maintain euglycemia. Erythrocytes were infused to compensate for
162 withdrawn blood. [$3\text{-}^3\text{H}$]-glucose kinetics were determined at -15 min and -5 min (basal period) and
163 every 10 min between 80-120 min to assess whole-body glucose appearance (R_a), disappearance
164 (R_d), and endogenous glucose production ($\text{endo}R_a$). For tissue-specific index of glucose uptake
165 (R_g) intravenous $13 \mu\text{Ci}$ 2- $[^{14}\text{C}]$ -deoxyglucose ($[^{14}\text{C}]2\text{DG}$) was given at 120 min and blood samples
166 collected at 122, 125, 135, 145 and 155 min to assess $[^{14}\text{C}]2\text{DG}$ plasma disappearance. Plasma
167 [$3\text{-}^3\text{H}$]-glucose and $[^{14}\text{C}]2\text{DG}$, and tissue $[^{14}\text{C}]2\text{DG}$ -phosphate were measured as previously (27).
168 At 155 min, the mice were anesthetized, and harvested tissues freeze clamped. Protocol details
169 are available online at the Vanderbilt Mouse Metabolic Phenotyping Center (www.vmmmpc.org).

170 *RNAseq and Microarray.* For RNA seq human microvascular cells were treated with either
171 control or CD36 siRNA and 72 h later total RNA isolated (TRIzol Reagent, ThermoFisher Scientific),
172 and cleaned (RNeasy, Qiagen). Samples were submitted to the Washington University Genome
173 Technology Access Center (GTAC) for library preparation, sequencing and read alignment.
174 Normalization and differential gene expression used the integrated Differential Expression and
175 Pathway Analysis (iDEP) web platform (28). For microarrays total RNA (TRIzol) isolated from heart
176 of 4h fasted mice was analyzed using Whole Mouse Genome Oligo Microarray (Agilent Technology,
177 Santa Clara, CA) at the Washington University Functional Genomics Core of the Digestive Disease
178 Research Center.

179 **Human Study Protocols**

180 *Subjects:* Healthy unrelated African American men and women, between the ages of 18-50
181 years old were recruited and genotyped for the CD36 coding single nucleotide polymorphism (SNP)
182 rs3211938 (G/T). This SNP, which reflects positive selection pressure, is almost exclusive to
183 populations of African ancestry (where G-allele incidence is 20-25%) (9). The SNP inserts a stop
184 codon resulting in a truncated protein that is degraded. Partial CD36 protein deficiency is observed
185 in subjects carrying the G allele and complete deficiency is observed in subjects who are
186 homozygous (G/G) (10). Subjects were excluded from participating in the study for the following:
187 BMI >40 kg/m 2 , type 1 or 2 diabetes mellitus, cardiovascular disease including hypertension,
188 impaired renal or liver function, use of nitrates, or systemic glucocorticoid therapy. Participants
189 reported to the Vanderbilt Clinical Research Center (CRC) for pre-screening and blood collection.
190 DNA was extracted, genotyped for rs3211938, and G-allele carriers and noncarriers invited to a
191 screening visit for a medical history, physical exam, and laboratory analyses (blood cell count,
192 metabolic panel, pregnancy test).

193 Genomic DNA was extracted from peripheral blood with a salting-out precipitation (Gentra
194 Puregene) and CD36 SNP rs3211938 detected using a predesigned TaqMan SNP genotyping
195 assay (Applied Biosystems) on a 7500 Fast (Applied Biosystems) instrument. Previous studies have
196 identified that the rs3211938 G allele reduces CD36 expression by 50% (9, 10). All human
197 assessments and studies were performed at the Vanderbilt CRC at 8 am in a quiet, temperature-
198 controlled room (22 to 23 °C). Participants were asked not to exercise or drink alcohol for at least
199 24 hours before the study and were contacted by the research nurse to remind them to fast the
200 night before. All participants underwent two visits at least 2 weeks apart. All studies adhered to
201 principles of the Declaration of Helsinki and Title 45 of the US Code of Federal Regulations (Part
202 46, Protection of Human Subjects). Studies were approved by the Vanderbilt Institutional Review
203 Board and conducted in accordance with institutional guidelines. All subjects provided informed
204 consent. The study was included in clinicaltrials.gov, identifier: NCT03012386

205 *Hyperinsulinemic-euglycemic (Insulin) Clamp:* During each visit, two intravenous (IV)
206 catheters were placed in the antecubital fossa of each arm. One of the catheters was used for drug
207 infusion, the other one for blood collection. A linear-array transducer connected to an ultrasound
208 was placed on the brachioradialis muscle of the arm not used for infusion. The transducer was used
209 to measure changes in microvascular circulation with contrast-enhanced ultrasonography (CEU)
210 and remained in the same position throughout the study.

211 On the first study day (saline day), participants received 0.9% standard saline infusion
212 (45ml/h) for 6 hours, and during the last three hours, a hyperinsulinemic-euglycemic (HIE) clamp.
213 Insulin was infused at a rate of $80 \text{ mU}\cdot\text{m}^{-2}\cdot\text{min}^{-1}$ for 5 min followed by $40 \text{ mU}\cdot\text{m}^{-2}\cdot\text{min}^{-1}$ for the
214 remainder of the study. Plasma glucose samples were obtained every 5 minutes throughout the
215 clamp and 5% glucose was infused at a variable rate to maintain plasma glucose between 90 to 95
216 mg/dl. Blood samples were collected for assay of plasma insulin.

217 The second study day was ~4 weeks later. Participants returned to the CRC and instead of
218 saline received a 6-hour IV infusion of 20% Intralipid® (Baxter Healthcare Crop. Glendale, CA) at a
219 rate of 45 ml/h and heparin (200 units prime followed by 200 units/hr.). Heparin was used to activate
220 endothelial lipoprotein lipase and accelerate lipolysis of triglycerides into fatty acids. The HIE clamp
221 was conducting during the last three hours of the study.

222 In both day visits, CEU measurements were obtained 3 hours after initiation of infusions
223 (saline or Intralipid® and heparin) during the insulin clamp. Intermittent blood pressures and ECG
224 were measured using the VITAL-GUARD 450c monitor (Ivy Biomedical Systems, Branford, CT).
225 Vanderbilt's Investigational Pharmacy conducted drug preparation, storage, and dispensing logs.

226 *Assessment of microvascular blood volume index:* Contrast-enhanced ultrasound imaging
227 used a linear-array transducer connected to an ultrasound (L9-3 mm transducer, iU22; Phillips).
228 Real-time imaging used low (0.08) and high (1.2) mechanical index. The contrast microbubbles
229 (Definity, Bristol-Myers Squibb) were infused at 1.5 ml/min for 10 min. At steady state (~4 min), the
230 1.2 mechanical index destroyed the microbubbles at the start of video recording. Switch to the low
231 index (0.08) made microbubbles resonate allowing real-time recording of vascular replenishment.
232 Local temperature was measured with a laser Non-Contact Infrared Skin Thermometer. Data were
233 analyzed using QLAB software.

234 *Clinical Chemistry:* Blood collected in chilled EDTA tubes was immediately centrifuged and
235 separated plasma stored at -80°C . For serum, blood clotted at room temperature for 20 minutes
236 was centrifuged and removed serum stored at -80°C . Plasma glucose was measured with a
237 glucose analyzer (YSI Life Sciences, Yellow Springs, OH). Plasma insulin concentrations were
238 determined by radioimmunoassay (Millipore, St. Charles, MO).

239 **Human microvascular cells (hMEC) protocols**

240 *CD36 knockdown, Caveolin 1-eNOS interaction:* Human derived primary dermal
241 microvascular cells, hMEC, (Lonza bioscience) were cultured in EGM-2 MV endothelial media
242 (Lonza) and passaged less than 5 times. Cells were treated with siRNA against CD36 (4392420,
243 assay ID 2646, ThermoFisher Scientific) or with control siRNA for 72 hours, as previously described
244 (28). The hMEC were serum starved for 4 h before adding human insulin (100nM, Sigma) for the
245 indicated times. For western blots, cells were lysed 20 min in ice-cold RIPA buffer (20 mM Tris-HCl,
246 pH 7.5, 150 mM NaCl, 1mM Na₂EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM
247 sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na₃VO₄, 1 $\mu\text{g}/\text{mL}$ leupeptin, 1mM
248 PMSF, and 1 $\mu\text{g}/\text{mL}$ protease inhibitor mix). Cleared lysates (10,000 x g, 10 min) were assayed for
249 protein content (DC Protein Assay, Bio-Rad). Separated proteins (30 μg , 4%–20% gradient gels,
250 ThermoFisher Scientific) were transferred to polyvinylidene membranes (Immobilon FI, Millipore),
251 blocked (1X TBS, 0.25% fish gelatin, 0.01 % Na-azide, 0.05% Tween-20) and primary antibodies
252 added overnight at 4°C . Washed membranes were treated 1h with infrared dye-labeled secondary
253 antibodies (RT, LI-COR Biosciences) and imaged (LI-COR Odyssey Infrared). Primary antibodies
254 used: anti-human CD36 (R&D Systems, AF2519), anti-pS473-Akt (Cell Signal Technology, 4060),
255 total Akt (Cell Signal Technology, 4691), pS1177-eNOS (Cell Signal Technology, 9571), total-eNOS
256 (Cell Signal Technology, 32027) and beta-Actin (Santa Cruz Biotechnology, sc-47778).

257 For immunoprecipitation (IP) 4h serum-starved hMECs were treated with insulin (100nM
258 10min, 37°C) then washed cells were scraped into 1 ml IP buffer (0.1 M NaCl, 0.3 M Sucrose, 30mM
259 MgCl₂, 10 mM PIPES, 0.5mM EDTA, 0.1% Nonidet P-40, protease and phosphatase inhibitors

260 and 0.5 mM pervanadate) kept on ice 20 min, then lysed by passage 5 times through a 25-gauge
261 needle. Aliquots (50 μ g protein) of clarified (11,000 x g, 10 min) lysates were incubated 5h with
262 Cav-1 antibody (Cell Signaling Technology, 3238) coupled to protein G magnetic beads
263 (Dynabeads, ThermoFisher). Rabbit IgG-coupled beads were controls. Immune complexes were
264 separated magnetically, washed (IP buffer) and boiled in 50 μ L of 2X SDS-Sample buffer prior to
265 SDS-PAGE (4-12%).

266 *Nitric Oxide measurement:* The Nitrate/Nitrite Colorimetric Assay (Cayman Chemicals,
267 780001) was used. Human insulin (Sigma, I9278) was added (100nM, 10 min) to 4 h serum
268 starved cells and media collected for NO measurement as per the manufacturer's protocol.

269 **Biostatistics**

270 Data are presented as means \pm standard errors of the mean (SEM). Data were log-transformed
271 prior to statistical testing when not normally distributed by the Shapiro–Wilks test. Summary data
272 were analyzed by a paired, parametric, two-tailed Student t test. P values of <0.05 were considered
273 significant (**** $P \leq 0.0001$, *** $P \leq 0.001$, ** $P \leq 0.01$, * $P \leq 0.05$, ns $P > 0.05$). All analyses used Prism
274 10.0 (GraphPad Software, La Jolla, CA).

275

276 **Results**

277 ***Cd36*^{-/-} mice have enhanced systemic glucose disposal and muscle insulin signaling.**

278 Hyperinsulinemic glucose clamps were performed in mice following a 5 h fast and a period
279 of basal sampling. *Cd36*^{-/-} mice have slightly smaller body weight than WT mice (**Fig. 1A**),
280 on average around 8% with similar lean body mass (29). Under basal conditions, plasma
281 insulin was similar for WT and *Cd36*^{-/-} mice but the latter group had lower arterial glucose,
282 in line with earlier studies (15, 16). Clamping glucose during equivalent hyperinsulinemia
283 required a significantly higher GIR in *Cd36*^{-/-} than in WT (**Fig. 1B, C, D**). Whole body rate
284 of disposal (Rd) was increased during the clamp in *Cd36*^{-/-} compared to WT mice (**Fig. 1E**)
285 and the *Cd36*^{-/-} mice displayed greater % suppression of endogenous rate of appearance
286 (Ra) during the insulin clamp (85% versus 59%) (**Fig. 1F**). The delta and percent
287 suppression of Ra were both significant. The absolute Ra was close to being significant
288 <0.069 and lower Ra contributes to GIR. The estimated contribution of Rd and Ra to the
289 greater GIR was respectively 2:1.

290 As compared to WT mice, *Cd36*^{-/-} mice had higher glucose uptake (Rg) in leg
291 skeletal muscle (superficial vastus lateralis and soleus) as well as in brown and

292 subcutaneous white adipose tissues. Glucose uptake by the heart and gastrocnemius
293 trended higher but did not reach significance (**Fig. 1G, H**). The hyperinsulinemic glucose
294 clamp data support the interpretation that CD36 deletion improves insulin-stimulated
295 glucose disposal through increases in Rd and in insulin suppression of endogenous Ra.

296 *Muscle insulin signaling is enhanced in Cd36^{-/-} mice:* The enhanced insulin
297 stimulated systemic glucose disposal observed in Cd36^{-/-} mice (**Figure 1**) is not
298 recapitulated in mice with muscle or cardiomyocyte specific CD36 deletion, which associate
299 with reduced expression of insulin signaling and glucose metabolism genes in muscle and
300 heart (5, 16). CD36 knockdown in cultured muscle cells also suppresses insulin action to
301 activate AKT by removing CD36 enhancement of insulin receptor phosphorylation and
302 signaling (5). We examined insulin activation of AKT in muscle of Cd36^{-/-} mice to determine
303 if it correlates with the enhanced glucose disappearance observed in these mice during the
304 insulin clamp. First, we confirmed as shown earlier (15) that Cd36^{-/-} mice as compared to
305 wildtype (WT) controls have enhanced glucose tolerance and are protected from glucose
306 intolerance induced by a high fat diet (HFD; 60% fat and 7% sucrose) (**Fig 2A, B, C**), ruling
307 out alterations in insulin action due to changes in mice environment or breeding. Insulin
308 signaling was assessed in muscle of 5h fasted WT and Cd36^{-/-} mice given 0.75 U/kg insulin
309 or saline (controls) intraperitoneally (IP). The mixed fiber quadriceps muscle was harvested
310 15 min after insulin injection and tissue lysates probed for AKT, pAKT and CD36. Muscles
311 of Cd36^{-/-} mice have similar basal AKT^{S473} and AKT^{T308} phosphorylation levels as WT mice
312 but a greatly enhanced insulin-stimulated AKT phosphorylation (~7 fold as compared to ~3
313 fold in WT) with no change in total AKT (**Fig. 2D, E,F**) consistent with enhanced muscle
314 insulin signaling and with the findings from the insulin clamp experiments.

315 We previously reported in 5h fasted Cd36^{-/-} mice significantly enhanced [¹⁸F]-
316 Fluorodeoxyglucose (2-FDG) uptake by various muscles. The fold increase over WT was
317 5 for heart , 4 for soleus, 3 for diaphragm and gastrocnemius and 2 for hindlimb (15).
318 Glycogen and triglyceride levels were reduced in heart and muscle. Examination of gene
319 expression in hearts from 5h fasted mice showed upregulation of genes that function in
320 insulin signaling or glucose utilization (**Fig. 2G**). Increased expression of Glut4 (Slc24, 1.8-
321 fold), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Pfkfb2), which regulates
322 glycolytic flux (2-fold), so is expression of hypoxia inducing factor HIF3a (2.6-fold) which

323 upregulates Pfkfb2 (30) and of glycogen synthase (Gys1, 4-fold) and Glycogen
324 phosphorylase (Pygm, 1.9-fold), which regulate glycogen turnover. Expression of PI3K, the
325 pathway that mediates insulin effects on glucose metabolism (pik3c2a and pik3cg) was 1.7-
326 fold higher, those of AKT2 (1.5-fold), AKT1 (1.45-fold) and AKT1 substrate 1 (2.3-fold). In
327 addition, fibroblast growth factor receptor 1 (FGFr1) a major target of FGF and potent
328 stimulator of glucose metabolism in muscle (31) is increased 1.9-fold, insulin like growth
329 factor receptor 1 (IGFR1), which binds IGF, and insulin is up 1.7-fold. Several integrins
330 (ITG) are upregulated. Integrins interact with the extracellular matrix and maintain cell
331 attachment, survival and growth by regulating the signaling of PI3K/AKT, growth factors
332 (FGF, IGF) and Src kinases (32). In addition to a 4.7-fold upregulation of ITGa7 (**Figure**
333 **2G**), there were increases in expression of ITGa9, 4.7-fold, ITGa5, 3-fold, and ITGa3, 2.3-
334 fold (data not shown). ITGA7/beta1 is the primary receptor for basement membrane laminin
335 in skeletal and heart myofibers and is important in regulating myofiber survival (33, 34).
336 Expression of Janus Kinase 3 (JAK3) which stimulates AKT-independent glucose uptake
337 (35) increased 3-fold **Figure 2G**.

338 ***Cd36*^{-/-} mice have normal transendothelial insulin flux but vascular dysfunction.**

339 *Insulin Flux:* Insulin access to muscle cells is regulated by the capillary endothelium,
340 which limits the rate of glucose disposal (19, 20). We examined whether CD36 deletion
341 might affect transendothelial insulin transport (EIT). To investigate this, we used the
342 exposed gastrocnemius preparation and intravital imaging of fluorescent insulin-647 (INS-
343 647) as described under methods and in greater detail previously (24). Plasma INS-647
344 dispersion to pericapillary interstitium was unaltered in *Cd36*^{-/-} mice. Plasma (**Fig. 3A**) and
345 interstitial INS-647 (**Fig. 3B**) was similar for *Cd36*^{-/-} and WT mice. The decrease in ratio of
346 plasma INS-647/interstitial INS-647, which measures rate of transfer of capillary insulin with
347 interstitial insulin was identical in both groups (**Fig. 3C**) with gradient decay constants of
348 $\sim 0.15 \text{ min}^{-1}$ (**Fig. 3D**). These data indicate that transendothelial insulin flux is not altered in
349 *Cd36*^{-/-} mice and did not contribute to the enhanced insulin stimulated glucose disposal.

350 *Capillary diameter and perfused area:* Fluorescence of rhodamine-dextran was used
351 to determine the capillary diameter (distance between glycocalyx on opposing endothelium)
352 and the perfused capillary cross sectional surface area. Capillary diameter (**Fig. 3E**) and
353 the perfused capillary surface area (**Fig. 3F**) are reduced by ~ 15 and $\sim 30\%$, respectively,

354 in $Cd36^{-/-}$ as compared to WT mice. The decrease in perfused capillary surface area is
355 unexpected considering the increased insulin action in $Cd36^{-/-}$ mice. To confirm this finding,
356 we examined changes in microvascular perfusion in $Cd36^{-/-}$ mice using another organ and
357 a different method. Arterial Spin Labeling Magnetic Resonance Imaging (ASL-MRI), a non-
358 invasive, quantitative measure of microvascular tissue perfusion (36) was used to estimate
359 renal perfusion. The ASL-MRI data (n=5 mice/group) collected at baseline under
360 anesthesia (1% isoflurane in 100% O₂) using a flow-sensitive (FAIR)-type ASL-MRI
361 protocol (37) revealed a 34% deficit (p<0.05) in capillary renal perfusion in $Cd36^{-/-}$ mice
362 (p<0.05) (data not shown) confirming the observation (**Fig. 3F**).

363 *Vessel compliance*: The increase in diameter of the carotid and aorta arteries in
364 response to increased intravascular pressure was examined for $Cd36^{-/-}$ mice and WT
365 controls. Vessels from $Cd36^{-/-}$ mice as compared to those from WT mice showed reduced
366 dilation as intravascular pressure increased from 0 to 175 mmHg in 25-mmHg steps (**Fig.**
367 **3G**). Thus, reduced vessel compliance might have contributed to measurements of smaller
368 capillary diameter and reduced capillary perfused surface area in $Cd36^{-/-}$ mice.

369 In summary insulin action on glucose uptake by muscle is enhanced in $Cd36^{-/-}$ mice
370 but this enhancement is independent of microvascular adaptations that improve insulin
371 delivery. Transcapillary flux of insulin is normal in $Cd36^{-/-}$ mice, however there is evidence
372 of endothelial dysfunction manifested by a diminished perfused capillary area and reduced
373 vessel compliance. Although endothelial dysfunction normally associates with diminished
374 glucose disposal, paradoxically in the case of CD36 deficiency it coexists with a higher
375 insulin stimulated glucose disposal.

376 **Individuals with partial CD36 deficiency have enhanced insulin response of glucose** 377 **disposal but microvascular insulin resistance.**

378 Common SNPs that reduce CD36 protein have been identified in many populations
379 including African Americans (38) and Caucasians (10). Carriers of the G-allele of coding
380 SNP 3211938 have 50% of normal CD36 levels (9, 38). We previously reported on
381 presence of endothelial dysfunction in these individuals (9) but there is no information on
382 whether this associates with improved or compromised insulin sensitivity.

383 *Demographic Characteristics of subjects*: Thirty-five subjects were screened,
384 fourteen were excluded for not meeting inclusion criteria or withdrew consent, and twenty-

385 one completed the study. Participants were divided into two groups based on the CD36
386 rs3211938 genotype. Controls (n=13) were homozygous for the major allele (T/T) and have
387 normal CD36 expression, whereas carriers (n=8) of the minor allele G (G/T) have ~50%
388 reduced CD36 expression (9, 10, 38). Only one subject was homozygous (G/G) with 100%
389 reduced CD36 expression and was included with the G/T cohort. The G-allele carriers were
390 on average 8 year older than non-carriers and their average weight trended lower. Fasting
391 glucose and triglyceride levels were similar. No participants were hypertensive; systolic
392 (SBP) and diastolic blood pressure (DBP) were similar. All participants were healthy and
393 not taking medications except for birth control in women (**Table 1**).

394 *Insulin fails to increase microvascular blood volume in G-allele carriers: We*
395 *examined insulin recruitment of the microvasculature in rs3211938 G-allele carriers (G/T)*
396 *and control non-carriers (T/T). In non-carriers insulin increased microvascular blood volume*
397 *index (MBV_i) from 8.4±0.63 to 11.3±1.37 (35%, p=0.05). In contrast, no insulin-induced*
398 *increase occurred in G-allele carriers (G/T) (**Fig. 4A**). Intralipid infusion instead of saline*
399 *before the hyperinsulinemic clamp blunted insulin's effect on microvascular recruitment in*
400 *non-carriers and G-carriers remained unresponsive (**Fig. 4B**).*

401 *Enhanced whole body insulin sensitivity in G-allele carriers versus non-carriers:*
402 *CD36 SNPs have been linked to the metabolic syndrome and T2D, but there is no definitive*
403 *data on whether CD36 deficient subjects are insulin sensitive or resistant. We determined*
404 *the glucose infusion rate (GIR) in both groups (G-allele carriers and noncarriers) during a*
405 *continuous insulin infusion at a dose of 40 mU/m²/min. The G-allele carriers required 1.9-*
406 *fold higher GIR than non-carriers, indicating they were more insulin sensitive (**Fig. 4C**).*
407 *Intralipid infusion decreased GIR in both carriers and non-carriers and the G-allele carriers*
408 *were no longer more insulin sensitive as compared to non-carriers (**Fig. 4D**). The increased*
409 *GIR in G-allele carriers during saline infusion did not reflect differences in insulin levels*
410 *during the steady state phase of the clamp (**Fig. 4E**) and similar insulin concentrations were*
411 *also measured during the intralipid infusion (**Fig. 4F**).*

412 In summary the insulin clamp findings indicate enhanced GIR supporting better
413 insulin stimulated glucose utilization in G-allele carriers. This enhancement occurs without
414 insulin stimulation of MVB flow, which suggests insulin resistance of the microvasculature
415 in individuals with partial CD36 deficiency.

416 **CD36 knockdown in human microvascular cells impairs insulin action and eNOS**
417 **activation.**

418 Signaling by insulin contributes to active maintenance of blood vessels through regulated
419 production of NO by endothelial nitric oxide synthase (eNOS) and polymorphisms in eNOS
420 associate with insulin resistance and T2D (39). To gain insight into the mechanism of the
421 microvascular insulin resistance in G-allele carriers, we investigated role of CD36 in insulin
422 regulation of eNOS using primary human-derived microvascular endothelial cells, hMEC,
423 which express high levels of CD36, a microvascular signature gene (28, 40).

424 *CD36 depletion in hMEC influences gene expression and insulin action:* Cells were
425 treated with either control siRNA or anti CD36 siRNA. First, the resulting alterations in gene
426 expression were determined by RNA seq (**Fig. 5A**). CD36 depletion associated with
427 increased expression of FGF1, insulin like growth factor 1 (IGF1), Jak3, PIK3 catalytic
428 domain and various integrins (ITG) including ITGA11, ITGA4, ITGA5 and ITGB5. Integrins
429 regulate signaling by PI3K and growth factors (32). Overall, the above upregulated genes
430 function to promote glucose utilization and cell survival, either directly or through activation
431 of PI3K/AKT and growth factor signaling (32, 35).

432 We previously showed that CD36 expression in human derived primary muscle cells
433 facilitates IR signaling and its depletion suppresses insulin activation of AKT (5). The hMEC
434 were tested for insulin responsiveness and the effect of CD36 knockdown. The hMEC
435 behaved like the human muscle cells; they responded to insulin with robust phosphorylation
436 of the activating sites of AKT^{S473} and eNOS^{S1177}, and CD36 knockdown significantly
437 suppressed insulin activation of both proteins (**Fig. 5B, C, D**).

438 *Interaction of eNOS with Caveolin-1:* In endothelial cells, Cav-1 interaction with
439 eNOS regulates eNOS activity and this interaction is enhanced by insulin (41, 42). CD36
440 resides in caveolae and can influence Cav-1 dynamics (28) so we examined whether CD36
441 it influences insulin regulation of the Cav-1/eNOS interaction. Immunoprecipitation of Cav-
442 1 from control and CD36 depleted hMEC showed, consistent with previous findings, that
443 insulin enhances interaction of Cav-1 with eNOS in control cells (41). Interestingly, CD36
444 depletion eliminated the effect of insulin on Cav-1/eNOS interaction (**Fig. 5E**). In addition,
445 consistent with CD36 knockdown acting to suppress insulin activation of eNOS, insulin-
446 stimulated NO production was simultaneously reduced (**Fig. 5F**).

447 Together these data support influence of endothelial CD36 on insulin-induced eNOS
448 activation and NO production and suggest that CD36 depletion associates with endothelial
449 insulin resistance and reduced NO availability. These data are consistent with the lack of
450 insulin induced increase in microvascular volume that is observed in G-allele carriers by
451 the hyperinsulinemic clamps (**Fig. 4A**) and the defect in arterial flow mediated dilation and
452 low cGMP levels previously described in these individuals (9). They are also consistent with
453 the observed vascular dysfunction; reduced capillary perfusion and vessel compliance, in
454 *Cd36*^{-/-} mice (**Fig. 3 E, F, G**).

455 Defects in microvascular insulin action and NO production and reduced endothelial
456 compliance are a hallmark of metabolic disease and thought to be involved in etiology of
457 T2D (43, 44). Previously we applied Predixcan analysis to a large patient sample in the
458 BioVu database of Vanderbilt University and documented that genetically determined low
459 CD36 mRNA in muscle or heart strongly associates with incidence of type 2 diabetes (T2D)
460 and its complications (5). PrediXcan estimates for GWAS samples the Genetically
461 Regulated eXpression (GReX) of a gene in specific tissues and uses GReX to identify
462 genes associated with disease risk (45, 46). We again used PrediXcan to test whether the
463 association holds if the analysis considers CD36 mRNA in blood or arteries. We found that
464 low vascular CD36 levels associates with T2D and its renal, ophthalmic, and neurological
465 manifestations (**Table 2**).

466 **Discussion**

467 The coding CD36 SNP rs3211938 (T/G) is the major cause of CD36 deficiency in African
468 Americans with an incidence of 9-12% for homozygous (G/G) and 20-25% for heterozygous
469 (G/T) (9, 10). In Japanese, CD36 deficiency has a frequency of 3% for homozygous and
470 6% for heterozygous (14). Total deficiency is low in Caucasians (0.3%) but SNPs that
471 reduce CD36 expression are relatively common (5-40%) (6, 11). CD36 SNPs often
472 associate with high circulating lipids, FA (6, 9) and chylomicron remnants (11, 47) and with
473 risk of metabolic syndrome (10, 48) and T2D coronary heart disease (6). We identified in
474 the BioVu patient biobank association of low heart and muscle CD36 mRNA with T2D renal,
475 ophthalmic and neurologic complications (5) and now confirm this association for low blood
476 and vascular CD36 (**Table 2**). Mechanisms underlying CD36 link to T2D are largely unclear.

477 There is currently no data to support a link between CD36 deficiency and insulin
478 resistance of glucose metabolism. A few studies in Japanese with CD36 deficiency
479 documented blood lipid abnormalities but provided no definitive answer related to presence
480 of insulin resistant glucose disposal (12, 49). In this study, our hyperinsulinemic euglycemic
481 clamps in individuals with partial CD36 deficiency (G-allele carriers) (9) and matched
482 controls document enhanced insulin stimulated glucose disposal in the CD36 deficient
483 group, like what is observed in CD36 deficient mice. The enhanced insulin stimulated
484 glucose disposal in G-allele carriers occurs without the insulin induced increase in
485 microvascular blood volume. The MVB increase which normally enhances insulin delivery
486 to muscle (19, 20) does not play a role in the improved insulin stimulated glucose disposal
487 of G-allele carriers. The lack of insulin MVB response suggests presence of selective
488 microvascular insulin resistance in G-allele carriers as compared to non-carriers (**Fig. 4A**).
489 This finding is consistent with the previous demonstration of impaired flow mediated dilation
490 of the brachial artery and low cGMP levels in these individuals, suggesting low NO
491 bioavailability (9). Our data with hMEC (**Fig. 5**) directly link insulin resistance to endothelial
492 dysfunction of the microvasculature. CD36 knockdown, blocks insulin signaling to AKT and
493 insulin activation of eNOS and NO release. This provides a plausible mechanism for the
494 endothelial dysfunction present in humans with partial CD36 deficiency and would apply to
495 the reduced capillary perfusion and vessel compliance observed in *Cd36*^{-/-} mice.
496 Importantly in CD36 deficiency the microvascular dysfunction did not cause insulin
497 resistance of glucose metabolism as would have been expected and as previously shown
498 in obese mice (50). The major difference in the case of CD36 deficiency is that it reduces
499 FA uptake and is critical endothelial FA transcytosis (16, 28). Infusion of intralipid in our
500 study blunted the effect of insulin to increase MVB in non-carriers and reduced GIR in both
501 groups (**Fig. 3B, C, D**) indicating that partial CD36 deficiency does not protect against
502 excess intake. CD36 deficiency protects from the muscle insulin resistance induced by high
503 fat feeding (**Fig. 2**) (15). The lack of protection in humans could reflect the difference
504 between effects of total (mice) versus partial CD36 deficiency (G-allele carriers). However,
505 uptake of FA from chylomicrons is not mediated by CD36 (51, 52) and the same is likely to
506 apply to lipid emulsions infused along with heparin. In both cases lipolysis results in
507 excessively high FA levels at the endothelial interface and under such conditions FA uptake
508 is independent of CD36.

509 Our studies in *Cd36*^{-/-} mice provide data that parallel and support interpretation of
510 the findings in CD36 deficient humans. Enhanced insulin stimulated glucose uptake by
511 heart, various muscles and adipose tissues, and better suppression of endogenous glucose
512 production by the liver are observed in *Cd36*^{-/-} mice as compared to controls (**Figs. 1, 2**).
513 The enhancement in insulin action on glucose metabolism in muscle, liver and adipose
514 tissue of *Cd36*^{-/-} mice occurs despite a reduced capillary perfusion area and impaired vessel
515 compliance in these mice. The mice studies, like the human studies indicate that enhanced
516 capillary insulin delivery does not contribute to the improvement in insulin stimulated
517 glucose disposal. The data in mice suggest an important role for the adaptive transcriptional
518 remodeling of muscle in CD36 deficiency, where there is upregulated expression of GLUT4,
519 of PI3K/AKT and of enzymes of glucose utilization. In addition, the primary receptors for
520 two potent stimulators of muscle glucose uptake FGF-R1 and IGF-R1 are upregulated.
521 Interestingly, expression of the corresponding growth factors FGF1 and IGF1 is increased
522 in hMEC after CD36 knockdown, as compared to the low levels in cells treated with control
523 siRNA. CD36 antagonizes effects of growth and pro-angiogenic factors in EC (53). As its
524 deletion relieves this negative regulation, one can speculate that this increases endothelial
525 release of FGF1 and IGF-1 by CD36 deficient EC. Interaction of the growth factors with
526 their receptors in muscle would enhance glucose uptake and utilization.

527 The endothelium can regulate insulin-stimulated glucose disposal through
528 controlling insulin delivery to muscle (20), through release of NO (54, 55) and other
529 bioactive molecules (56) or the secretion of exosomes (28). Endothelial insulin resistance
530 is thought to be a precursor of muscle insulin resistance and the reduced NO availability
531 was implicated in driving insulin resistance of glucose metabolism in obese mice (50).
532 However, an opposite outcome like the one we describe in G-allele carriers was reported
533 in a recent study where inducing EC specific insulin resistance by disabling endothelial IR
534 and IGF-1R, enhanced muscle and fat insulin sensitivity (57). Increased expression of
535 NADPH oxidase 4 and consequent endothelial release of peroxide were suggested as
536 mediators. We do not observe increased NADPH oxidase 4 expression in CD36 deficient
537 EC, although we do not rule out its potential contribution. In the case of CD36 deficiency
538 we believe the effect might be linked to the absence of endothelial FA uptake. Endothelial
539 cell CD36 controls delivery of circulating FA to heart and muscle (16) through a transfer
540 mechanism that involves generation and secretion of CD36-containing FA-exosomes.

541 These EC derived exosomes can regulate muscle gene expression and metabolic
542 adaptation (28). The exosome cargo and how it is altered in obesity or with excess fat intake
543 will need to be examined as this might shed more light on the role of the endothelium in
544 regulating insulin resistance.

545 In conclusion partial CD36 deficiency in humans, as observed in CD36 deficient mice
546 increases insulin-stimulated glucose utilization, which energetically compensates for the
547 suppressed FA uptake. Some limitations apply to our hyperinsulinemic euglycemic studies
548 in humans notably the relatively small number of subjects studied (13 controls and 8 G-
549 allele carriers). However, study participants underwent in-depth metabolic phenotyping
550 before matching the cohorts. The small difference in weight between the cohorts is another
551 limitation but it was addressed through adjusting the glucose infusion rate by weight.

552 The evidence provided in this study support the role of CD36 deficiency in
553 microvascular insulin resistance and reduced NO bioavailability (**Fig. 4 and 5**). Although
554 this impairment does not associate with reduced muscle glucose disposal and instead
555 enhances it, the long-term effects of this dysfunction within the context of obesity are likely
556 to be detrimental and could play an important role in the etiology of T2D complications.
557 Genetic data associate low CD36 mRNA in various tissues including heart, skeletal muscle
558 (5) and endothelium (**Table 2**) with T2D renal, ophthalmic and neurologic complications,
559 which often reflect vascular impairments. A common CD36 haplotype in Caucasians
560 associates with coronary heart disease in diabetics (6). The defect in NO production in
561 CD36 deficiency identified in both CD36 deficient mice and humans is likely to contribute
562 to etiology of the microvascular complications of T2D and could be targeted to prevent or
563 mitigate these abnormalities.

564 *Acknowledgments:* We acknowledge support of National Institute of Health RO1DK111175
565 (NAA, CAS, NNA), NHLBI R01HL157584 (CAS), NHLBI R01 HL045095 (IJG, NAA) and
566 Clinical Translational Science Award (CTSA) 5UL1TR002243-03 (CAS), and assistance of
567 Vanderbilt Institute for Clinical and Translational Sciences and Washington University
568 Nutrition and Obesity Center (NORC, NIH P30 DK056341).

569

570 **Figure legends:**

571 **Figure 1. CD36 deletion in mice improves insulin sensitivity and the glucose**
572 **metabolic index.** Hyperinsulinemic-euglycemic clamps were performed in awake, non-
573 restrained wildtype (WT) and *Cd36*^{-/-} mice. **A.** Body weight. **B.** Fasting and clamp insulin
574 was similar in both genotypes. **C.** Reduced fasting glucose in *Cd36*^{-/-} but similar blood
575 glucose levels in WT and *Cd36*^{-/-} mice during the clamp. **D.** Higher glucose infusion rates
576 were needed to maintain euglycemia in *Cd36*^{-/-} mice compared to WT. **E.** Glucose
577 disappearance rates are higher in *Cd36*^{-/-} mice during the clamp. **F.** Insulin more effectively
578 suppresses endogenous glucose production in *Cd36*^{-/-} mice. **G and H.** Glucose metabolic
579 index in superficial vastus muscle (SVL), soleus, (SubQ AT), and brown adipose tissue
580 (BAT) in *Cd36*^{-/-} mice as compared to WT mice. Gastrocnemius (gastroc), peri-gonadal
581 adipose tissue (PG AT), and heart glucose metabolic index were elevated but differences
582 did not reach significance. As expected, brain glucose metabolic index was equivalent in
583 WT and *Cd36*^{-/-} mice. Data are mean ± SE. n=5-7 *p<0.05, **p<0.01, ***p<0.001,
584 ****p<0.0001.

585 **Figure 2. Insulin signaling is enhanced in muscle of *Cd36*^{-/-} mice.** **A.** Intraperitoneal
586 glucose tolerance test (IGTT) in 5h fasted mice fed a chow diet. **B.** IGTT and **C.** insulin
587 sensitivity test in mice fed a high fat diet for 12 weeks. **D.** Muscle insulin sensitivity: WT
588 mice and *Cd36*^{-/-} mice were fasted for 5h, then insulin (7.5 IU/kg) was given
589 intraperitoneally, the gastrocnemius was harvested 15 min later and probed for CD36,
590 pAKT and total AKT. **E.** Levels of insulin phosphorylated AKT at serine 473 and **F.** threonine
591 308, both adjusted for total AKT. N=5-6 mice group. **G.** Altered expression of genes related
592 to insulin signaling and glucose utilization shown as fold change of levels in *Cd36*^{-/-} as
593 compared to WT controls (n=4 per group).

594 **Figure 3. CD36 deletion on trans-endothelial insulin efflux kinetics in capillaries of**
595 **skeletal muscle** following a 2 U/kg bolus of insulin-647 in WT *Cd36*^{-/-} mice. **A.** Capillary
596 plasma INS-647 fluorescence. **B.** Interstitial INS-647 fluorescence. The interstitial space is
597 defined as the region extending 1-3 μm from the capillary wall. **C.** Ratio of plasma/interstitial
598 INS-647 intensity. **D.** The exponential decay constant of plasma/interstitial INS-647
599 gradient decay. **E.** Capillary diameter. **F.** Perfused capillary surface area, capillary diameter
600 and perfused surface area measured using 2 MDa tetramethylrhodamine-dextran

601 fluorescence as a vascular marker. The microvascular perfused area determined in the
602 kidney using FASL-MRI in WT and *Cd36*^{-/-} mice. Both measures of the perfused
603 microvascular area yielded a ~30% reduction in *Cd36*^{-/-} mice compared to WT mice. Data
604 are mean ± SE. n=5 per group. *p<0.05, **p<0.01.

605 **Figure 4. Hyperinsulinemic euglycemic clamp in individuals carrying the G allele**
606 **(G/T) of CD36 SNP rs3211938 with partial CD36 deficiency versus non-carriers**
607 **controls (T/T).** Participants received 0.9% standard saline infusion (45ml/h) for 6 hours,
608 and during the last three hours, a hyperinsulinemic-euglycemic (HIE) clamp. Insulin was
609 infused at a rate of 80 mU·m⁻²·min⁻¹ for 5 min followed by 40 mU·m⁻²·min⁻¹ for the remainder
610 of the study. **A.** Upper panel: Effect of insulin on microvascular blood volume index (MBVi).
611 Middle panel: Glucose infusion rate (GIR). Bottom panel: Circulating insulin levels were
612 similar G-allele carriers and noncarriers during basal and clamp periods. **B.** Participants
613 receives a 6-hour IV infusion of 20% Intralipid instead of saline before the three-hour HIE.
614 Upper panel: MVBi, middle panel: GIR, bottom panel: circulating insulin levels in basal and
615 clamp.

616 **Figure 5. CD36 regulates insulin signaling in primary derived human**
617 **microvascular cells (hMEC).** **A.** Alterations in genes related to PI3K-Insulin signaling in
618 control hMEC (Ctrl, treated with scrambled siRNA) and CD36KD (KD, hMEC treated with
619 anti-CD36 siRNA). **B.** Western blots of hMEC, Control (CtrlKD) and CD36KD showing effect
620 of insulin (100nM, 5min) on phosphorylation of AKT and eNOS. **C and D.** Densitometry
621 analysis of pAKT/total AKT and of p-eNOS/total eNOS (n=3 p<0.05). **E.** CD36 knockdown
622 on insulin-dependent interaction of Cav-1 and eNOS. Western blot is representative of
623 three independent experiments. **F.** CD36 regulation of NO production. Ctrl and CD36KD
624 hMEC were serum starved and subjected to insulin stimulation (100nM, 5min). n=4, assays.
625 *p<0.05, ****p<0.005, ****p<0.0001).

626

627

628

629

630

Table 1. Demographic characteristics of study participants

Values are means \pm standard error of the mean. P values were generated with Student's t-test.

	<u>G-allele</u> N=8	<u>Non-carriers</u> N=13	
Age, years	42 \pm 2.6	34 \pm 2.1	0.019*
Gender(m/f)	3/5	3/10	
Weight, kg	79 \pm 2.9	89 \pm 3.8	0.083
Glucose, mg/dL	81 \pm 3.8	86 \pm 5.4	0.511
Cholesterol, mg/dL	180 \pm 13.1	177 \pm 6.7	0.821
HDL, mg/dL	51 \pm 4.88	54 \pm 3.5	0.567
LDL, mg/dL	106 \pm 12.8	106 \pm 6.1	0.986
Triglycerides, mg/dL	116 \pm 26.1	83 \pm 10.9	0.189
SBP, mm Hg	124 \pm 4.7	120 \pm 2.4	0.349
DBP, mm Hg	75 \pm 3.6	77 \pm 2.5	0.857
HR, bpm	78 \pm 7.5	68 \pm 3.7	0.206

647

648 **Table 2: Association of genetically determined low endothelial CD36 expression**
649 **with T2D status and complications.**

Tissue CD36	Effect	p-value	T2D and complications
Whole Blood	-4.323	0.000015	T2D + renal manifestations
Artery -Tibial	-4.058	0.00005	T2D + renal manifestations
Artery -Tibial	-3.506	0.00045	T2D + ophthalmic manifestations
Artery -Tibial	-3.434	0.00059	T2D + neurological manifestations

650 CD36 contribution to T2D risk was evaluated using PrediXcan analysis (45). The genetically
651 determined component of CD36 expression was estimated from gene expression
652 imputation trained with reference transcriptome data (N = 44 tissues, 449 donors, version
653 6p) from the Genotype-Tissue Expression (GTEx) Consortium. Analysis was applied to
654 4702 total patients of European ancestry with 1484 patients with T2D, in the BioVU
655 database (58) of Vanderbilt University where health records are tied to a DNA biobank.
656 Samples were genotyped, Illumina 660K, and genotype imputation used 1000 Genomes
657 Project (59) as reference. For replication of CD36 gene level association with T2D risk, we
658 used GWAS meta-analysis data on HOMA-IR from the MAGIC Consortium (60) and applied
659 PrediXcan to GWAS summary statistics. The replication data set had 37037 participants of
660 European ancestry.

661


662

663

664

665

666



667

668

669 **Figure 1: CD36 deletion in mice improves insulin sensitivity and the glucose**

670 **metabolic index.** Hyperinsulinemic-euglycemic clamps were performed in awake, non-

671 restrained wildtype (WT) and *Cd36*^{-/-} mice. **A.** Body weight. **B.** Fasting and clamp insulin

672 was similar in both genotypes. **C.** Reduced fasting glucose in *Cd36*^{-/-} but similar blood

673 glucose levels in WT and *Cd36*^{-/-} mice during the clamp. **D.** Higher glucose infusion rates

674 were needed to maintain euglycemia in *Cd36*^{-/-} mice compared to WT. **E.** Glucose

675 disappearance rates are higher in *Cd36*^{-/-} mice during the clamp. **F.** Insulin more effectively

676 suppresses endogenous glucose production in *Cd36*^{-/-} mice. **G-H.** Glucose metabolic index

677 in superficial vastus muscle (SVL), soleus, subcutaneous (SubQ AT), and brown adipose


678 tissue (BAT) in *Cd36*^{-/-} mice as compared to WT mice. Gastrocnemius (gastroc), peri-

679 gonadal adipose tissue (PG AT), and heart glucose metabolic index were elevated but

680 differences did not reach significance. As expected, brain glucose metabolic index was

681 equivalent in WT and *Cd36*^{-/-} mice. Data are mean ± SE. n=5-7 *p<0.05, **p<0.01,

682 ***p<0.001, ****p<0.0001.




683

684

685 **Figure 2: Enhanced Insulin signaling in muscle of *Cd36*^{-/-} mice.** **A.** Intraperitoneal (IP)
 686 glucose tolerance test (IPGTT) in 5h fasted mice showing enhanced glucose disposal in
 687 *Cd36*^{-/-} as compared to WT mice. **B.** IPGTT, and **C.** Insulin sensitivity test in mice after
 688 feeding a high fat diet (HFD) showing glucose intolerance in WT mice, while *Cd36*^{-/-} mice
 689 are protected. N=5-6 per group. **D.** 5h fasted *Cd36*^{-/-} mice and WT controls were given
 690 insulin (7.5 IU/kg) IP and the gastrocnemius muscles were harvested 15 min later and
 691 processed for Western blots. Shown are signals for CD36, pAKT^{S473} and total AKT. **E-F.**
 692 Levels of insulin phosphorylated AKT (S473 and T308) adjusted for total AKT. **G-H.**
 693 Enhanced S6 phosphorylation in gastrocnemius of *Cd36*^{-/-} mice as compared to WT mice
 694 and quantification of levels adjusted for total S6. **I.** Altered expression of genes related to
 695 insulin action and glucose metabolism in muscle of WT and *Cd36*^{-/-} mice, n=3 per group.
 696 *p<0.05, **p<0.01, ****p<0.0001.

697



698

699

700 **Figure 3: Trans-endothelial insulin efflux in muscle and the microvascular perfused**

701 **area.** WT and *Cd36*^{-/-} mice were given a 2 U/kg bolus of insulin-647. **A.** Capillary plasma

702 INS-647 fluorescence **B.** INS-647 in interstitial space extending 1-3 μm from capillary wall.

703 **C.** Plasma/interstitial INS-647 intensity. **D.** Exponential decay constant of plasma/interstitial

704 INS-647 gradient. **E.** Capillary diameter and **F.** Perfused capillary surface, both assessed

705 with 2 MDa tetramethylrhodamine-dextran fluorescence, a vascular marker, show ~30%

706 reduction in *Cd36*^{-/-} mice compared to WT mice. Data are means \pm SE. n=5 per group. **G.**


707 Intravascular pressure of carotid artery (left panel) and aorta (right panel) from *Cd36*^{-/-} mice

708 compared to WT mice (n=3/genotype). The vessels were mounted in saline on a pressure


709 arteriograph, pressurized and longitudinally stretched three times to *in vivo* length before

710 data capture. *p<0.05, **p<0.01.

711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733



734 **Figure. Hyperinsulinemic euglycemic clamp in individuals carrying the G allele**
735 **(G/T) of CD36 SNP rs3211938 with partial CD36 deficiency versus non-carriers**
736 **controls (T/T).** Participants received standard saline infusion (45ml/h) for 6 h, and a
737 hyperinsulinemic-euglycemic (HIE) clamp during the last three h. Insulin was infused at a
738 rate of 80 mU·m⁻²·min⁻¹ for 5 min followed by 40 mU·m⁻²·min⁻¹ for the rest of the study. **A.**
739 Upper panel: Effect of insulin on microvascular blood volume index (MBVi). Middle panel:
740 Glucose infusion rate (GIR). Bottom panel: Circulating insulin levels were similar for G-
741 allele carriers and noncarriers during basal and clamp periods. **B.** Participants received a
742 6-hour IV infusion of 20% Intralipid before the three-hour HIE. Upper panel: MBVi, middle
743 panel: GIR, bottom panel: circulating insulin levels. *P=0.05



744
 745 **Figure 5. CD36 regulates insulin signaling in primary derived human microvascular**
 746 **cells (hMEC).** **A.** Alterations in genes related to PI3K-Insulin signaling in control hMEC
 747 (Ctrl, treated with scrambled siRNA) and CD36KD (KD, hMEC treated with anti-CD36
 748 siRNA). **B.** Western blots of hMEC, Control (CtrlKD) and CD36KD showing effect of insulin
 749 (100nM, 5min) on phosphorylation of AKT and eNOS. **C and D.** Densitometry analysis of
 750 pAKT/total AKT and of p-eNOS/total eNOS (n=3 p<0.05). **E.** CD36 knockdown on insulin-
 751 dependent interaction of Cav-1 and eNOS. Western blot is representative of three
 752 independent experiments. **F.** CD36 regulation of NO production. Ctrl and CD36KD hMEC
 753 were serum starved and subjected to insulin stimulation (100nM, 5min). n=4, assays.
 754 *p<0.05, ****p<0.005.

755
 756
 757
 758
 759

760 References

- 761 1. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM,
762 Trembling PM, Mann CJ, Shoulders CC, et al. Identification of Cd36 (Fat) as an insulin-
763 resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats.
764 *Nat Genet.* 1999;21(1):76-83.
- 765 2. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, Aitman TJ, Glazier AM,
766 Ibrahimi A, Abumrad NA, et al. Transgenic rescue of defective Cd36 ameliorates insulin
767 resistance in spontaneously hypertensive rats. *Nat Genet.* 2001;27(2):156-8.
- 768 3. Corpeleijn E, van der Kallen CJ, Kruijshoop M, Magagnin MG, de Bruin TW, Feskens EJ,
769 Saris WH, and Blaak EE. Direct association of a promoter polymorphism in the CD36/FAT
770 fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance. *Diabet*
771 *Med.* 2006;23(8):907-11.
- 772 4. Lepretre F, Vasseur F, Vaxillaire M, Scherer PE, Ali S, Linton K, Aitman T, and Froguel P.
773 A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes.
774 *Hum Mutat.* 2004;24(1):104.
- 775 5. Samovski D, Dhule P, Pietka T, Jacome-Sosa M, Penrose E, Son NH, Flynn CR, Shoghi
776 KI, Hyrc KL, Goldberg IJ, et al. Regulation of Insulin Receptor Pathway and Glucose
777 Metabolism by CD36 Signaling. *Diabetes.* 2018;67(7):1272-84.
- 778 6. Ma X, Bacci S, Mlynarski W, Gottardo L, Soccio T, Menzaghi C, Iori E, Lager RA, Shroff
779 AR, Gervino EV, et al. A common haplotype at the CD36 locus is associated with high free
780 fatty acid levels and increased cardiovascular risk in Caucasians. *Hum Mol Genet.*
781 2004;13(19):2197-205.
- 782 7. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM,
783 Kwiatkowski D, Greenwood BM, Snow RW, et al. Malaria susceptibility and CD36
784 mutation. *Nature.* 2000;405(6790):1015-6.
- 785 8. Lee K, Godeau B, Fromont P, Plonquet A, Debili N, Bachir D, Reviron D, Gourin J,
786 Fernandez E, Galacteros F, et al. CD36 deficiency is frequent and can cause platelet
787 immunization in Africans. *Transfusion.* 1999;39(8):873-9.
- 788 9. Shibao CA, Celedonio JE, Ramirez CE, Love-Gregory L, Arnold AC, Choi L, Okamoto LE,
789 Gamboa A, Biaggioni I, Abumrad NN, et al. A Common CD36 Variant Influences
790 Endothelial Function and Response to Treatment with Phosphodiesterase 5 Inhibition. *J*
791 *Clin Endocrinol Metab.* 2016;101(7):2751-8.
- 792 10. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, Doria A, Rao DC, Hunt SC,
793 Klein S, Neuman RJ, et al. Variants in the CD36 gene associate with the metabolic
794 syndrome and high-density lipoprotein cholesterol. *Hum Mol Genet.* 2008;17(11):1695-
795 704.
- 796 11. Love-Gregory L, Kraja AT, Allum F, Aslibekyan S, Hedman AK, Duan Y, Borecki IB, Arnett
797 DK, McCarthy MI, Deloukas P, et al. Higher chylomicron remnants and LDL particle
798 numbers associate with CD36 SNPs and DNA methylation sites that reduce CD36. *J Lipid*
799 *Res.* 2016;57(12):2176-84.
- 800 12. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, and Matsuzawa Y. CD36
801 deficiency associated with insulin resistance. *Lancet.* 2001;357(9257):686-7.
- 802 13. Furuhashi M, Ura N, Nakata T, and Shimamoto K. Insulin sensitivity and lipid metabolism
803 in human CD36 deficiency. *Diabetes Care.* 2003;26(2):471-4.
- 804 14. Kajihara S, Hisatomi A, Ogawa Y, Yasutake T, Yoshimura T, Hara T, Mizuta T, Ozaki I,
805 Iwamoto N, and Yamamoto K. Association of the Pro90Ser CD36 mutation with elevated
806 free fatty acid concentrations but not with insulin resistance syndrome in Japanese. *Clin*
807 *Chim Acta.* 2001;314(1-2):125-30.
- 808 15. Hajri T, Han XX, Bonen A, and Abumrad NA. Defective fatty acid uptake modulates insulin
809 responsiveness and metabolic responses to diet in CD36-null mice. *J Clin Invest.*
810 2002;109(10):1381-9.

- 811 16. Son NH, Basu D, Samovski D, Pietka TA, Peche VS, Willecke F, Fang X, Yu SQ, Scerbo
812 D, Chang HR, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake. *J Clin Invest.*
813 2018;128(10):4329-42.
- 814 17. Laakso M, Edelman SV, Brechtel G, and Baron AD. Decreased effect of insulin to
815 stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin
816 resistance. *J Clin Invest.* 1990;85(6):1844-52.
- 817 18. Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S, and Barrett EJ. The vasodilatory
818 actions of insulin on resistance and terminal arterioles and their impact on muscle glucose
819 uptake. *Diabetes Metab Res Rev.* 2004;20(1):3-12.
- 820 19. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, and Barrett EJ.
821 Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose
822 uptake in vivo. *Diabetes.* 2004;53(6):1418-23.
- 823 20. Williams IM, and Wasserman DH. Capillary Endothelial Insulin Transport: The Rate-
824 limiting Step for Insulin-stimulated Glucose Uptake. *Endocrinology.* 2022;163(2).
- 825 21. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, and Yki-Jarvinen H.
826 Marked resistance of the ability of insulin to decrease arterial stiffness characterizes
827 human obesity. *Diabetes.* 1999;48(4):821-7.
- 828 22. Knutsen RH, Beeman SC, Broekelmann TJ, Liu D, Tsang KM, Kovacs A, Ye L, Danback
829 JR, Watson A, Wardlaw A, et al. Minoxidil improves vascular compliance, restores
830 cerebral blood flow, and alters extracellular matrix gene expression in a model of chronic
831 vascular stiffness. *Am J Physiol Heart Circ Physiol.* 2018;315(1):H18-H32.
- 832 23. Wagenseil JE, Nerurkar NL, Knutsen RH, Okamoto RJ, Li DY, and Mecham RP. Effects of
833 elastin haploinsufficiency on the mechanical behavior of mouse arteries. *Am J Physiol*
834 *Heart Circ Physiol.* 2005;289(3):H1209-17.
- 835 24. Williams IM, Valenzuela FA, Kahl SD, Ramkrishna D, Mezo AR, Young JD, Wells KS, and
836 Wasserman DH. Insulin exits skeletal muscle capillaries by fluid-phase transport. *J Clin*
837 *Invest.* 2018;128(2):699-714.
- 838 25. Ayala JE, Bracy DP, Malabanan C, James FD, Ansari T, Fueger PT, McGuinness OP, and
839 Wasserman DH. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. *J*
840 *Vis Exp.* 2011(57).
- 841 26. Berglund ED, Li CY, Poffenberger G, Ayala JE, Fueger PT, Willis SE, Jewell MM, Powers
842 AC, and Wasserman DH. Glucose metabolism in vivo in four commonly used inbred
843 mouse strains. *Diabetes.* 2008;57(7):1790-9.
- 844 27. Lantier L, Williams AS, Williams IM, Yang KK, Bracy DP, Goelzer M, James FD, Gius D,
845 and Wasserman DH. SIRT3 Is Crucial for Maintaining Skeletal Muscle Insulin Action and
846 Protects Against Severe Insulin Resistance in High-Fat-Fed Mice. *Diabetes.*
847 2015;64(9):3081-92.
- 848 28. Peche VS, Pietka TA, Jacome-Sosa M, Samovski D, Palacios H, Chatterjee-Basu G,
849 Dudley AC, Beatty W, Meyer GA, Goldberg IJ, et al. Endothelial cell CD36 regulates
850 membrane ceramide formation, exosome fatty acid transfer and circulating fatty acid
851 levels. *Nat Commun.* 2023;14(1):4029.
- 852 29. Hajri T, Hall AM, Jensen DR, Pietka TA, Drover VA, Tao H, Eckel R, and Abumrad NA.
853 CD36-facilitated fatty acid uptake inhibits leptin production and signaling in adipose tissue.
854 *Diabetes.* 2007;56(7):1872-80.
- 855 30. Minchenko O, Opentanova I, and Caro J. Hypoxic regulation of the 6-phosphofructo-2-
856 kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. *FEBS*
857 *Lett.* 2003;554(3):264-70.
- 858 31. Ying L, Wang L, Guo K, Hou Y, Li N, Wang S, Liu X, Zhao Q, Zhou J, Zhao L, et al.
859 Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. *Nat*
860 *Commun.* 2021;12(1):7256.

- 861 32. Grassian AR, Coloff JL, and Brugge JS. Extracellular matrix regulation of metabolism and
862 implications for tumorigenesis. *Cold Spring Harb Symp Quant Biol.* 2011;76(313-24.
- 863 33. Bugiardini E, Nunes AM, Oliveira-Santos A, Dagda M, Fontelonga TM, Barraza-Flores P,
864 Pittman AM, Morrow JM, Parton M, Houlden H, et al. Integrin alpha7 Mutations Are
865 Associated With Adult-Onset Cardiac Dysfunction in Humans and Mice. *J Am Heart*
866 *Assoc.* 2022;11(23):e026494.
- 867 34. Vachon PH, Xu H, Liu L, Loechel F, Hayashi Y, Arahata K, Reed JC, Wewer UM, and
868 Engvall E. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in
869 merosin-deficient congenital muscular dystrophy. *J Clin Invest.* 1997;100(7):1870-81.
- 870 35. Krolopp JE, Thornton SM, and Abbott MJ. IL-15 Activates the Jak3/STAT3 Signaling
871 Pathway to Mediate Glucose Uptake in Skeletal Muscle Cells. *Front Physiol.* 2016;7(626.
- 872 36. Kwong KK, Chesler DA, Weisskoff RM, Donahue KM, Davis TL, Ostergaard L, Campbell
873 TA, and Rosen BR. MR perfusion studies with T1-weighted echo planar imaging. *Magn*
874 *Reson Med.* 1995;34(6):878-87.
- 875 37. Beeman SC, Cullen-McEwen LA, Puelles VG, Zhang M, Wu T, Baldelomar EJ, Dowling J,
876 Charlton JR, Forbes MS, Ng A, et al. MRI-based glomerular morphology and pathology in
877 whole human kidneys. *Am J Physiol Renal Physiol.* 2014;306(11):F1381-90.
- 878 38. Love-Gregory L, Sherva R, Schappe T, Qi JS, McCrea J, Klein S, Connelly MA, and
879 Abumrad NA. Common CD36 SNPs reduce protein expression and may contribute to a
880 protective atherogenic profile. *Hum Mol Genet.* 2011;20(1):193-201.
- 881 39. Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, Valsecchi G, Lucotti
882 P, Pozza G, Bernardinelli L, et al. Endothelial nitric oxide synthase polymorphisms are
883 associated with type 2 diabetes and the insulin resistance syndrome. *Diabetes.*
884 2003;52(5):1270-5.
- 885 40. Nolan DJ, Ginsberg M, Israely E, Palikuqi B, Poulos MG, James D, Ding BS, Schachterle
886 W, Liu Y, Rosenwaks Z, et al. Molecular signatures of tissue-specific microvascular
887 endothelial cell heterogeneity in organ maintenance and regeneration. *Dev Cell.*
888 2013;26(2):204-19.
- 889 41. Chen Z, S DSO, Zimnicka AM, Jiang Y, Sharma T, Chen S, Lazarov O, Bonini MG, Haus
890 JM, and Minshall RD. Reciprocal regulation of eNOS and caveolin-1 functions in
891 endothelial cells. *Mol Biol Cell.* 2018;29(10):1190-202.
- 892 42. Wang H, Wang AX, Liu Z, Chai W, and Barrett EJ. The trafficking/interaction of eNOS and
893 caveolin-1 induced by insulin modulates endothelial nitric oxide production. *Mol*
894 *Endocrinol.* 2009;23(10):1613-23.
- 895 43. Hasan SS, and Fischer A. The Endothelium: An Active Regulator of Lipid and Glucose
896 Homeostasis. *Trends Cell Biol.* 2021;31(1):37-49.
- 897 44. Wasserman DH, Wang TJ, and Brown NJ. The Vasculature in Prediabetes. *Circ Res.*
898 2018;122(8):1135-50.
- 899 45. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, Eyler
900 AE, Denny JC, Consortium GT, Nicolae DL, et al. A gene-based association method for
901 mapping traits using reference transcriptome data. *Nat Genet.* 2015;47(9):1091-8.
- 902 46. Hale AT, Bastarache L, Morales DM, Wellons JC, 3rd, Limbrick DD, Jr., and Gamazon ER.
903 Multi-omic analysis elucidates the genetic basis of hydrocephalus. *Cell Rep.*
904 2021;35(5):109085.
- 905 47. Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M, Yamashita Y,
906 Takada M, Tsubakio-Yamamoto K, Tochino Y, et al. Chylomicron remnants are increased
907 in the postprandial state in CD36 deficiency. *J Lipid Res.* 2009;50(5):999-1011.
- 908 48. Farook VS, Puppala S, Schneider J, Fowler SP, Chittoor G, Dyer TD, Allayee H, Cole SA,
909 Arya R, Black MH, et al. Metabolic syndrome is linked to chromosome 7q21 and
910 associated with genetic variants in CD36 and GNAT3 in Mexican Americans. *Obesity*
911 *(Silver Spring).* 2012;20(10):2083-92.

- 912 49. Yanai H, Chiba H, Morimoto M, Jamieson GA, and Matsuno K. Type I CD36 deficiency in
913 humans is not associated with insulin resistance syndrome. *Thromb Haemost.*
914 2000;83(5):786.
- 915 50. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S,
916 Takamoto I, Sasako T, et al. Impaired insulin signaling in endothelial cells reduces insulin-
917 induced glucose uptake by skeletal muscle. *Cell Metab.* 2011;13(3):294-307.
- 918 51. Cabodevilla AG, Tang S, Lee S, Mullick AE, Aleman JO, Hussain MM, Sessa WC,
919 Abumrad NA, and Goldberg IJ. Eruptive xanthoma model reveals endothelial cells
920 internalize and metabolize chylomicrons, leading to extravascular triglyceride
921 accumulation. *J Clin Invest.* 2021;131(12).
- 922 52. Bharadwaj KG, Hiyama Y, Hu Y, Huggins LA, Ramakrishnan R, Abumrad NA, Shulman
923 GI, Blaner WS, and Goldberg IJ. Chylomicron- and VLDL-derived lipids enter the heart
924 through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty
925 acid uptake. *J Biol Chem.* 2010;285(49):37976-86.
- 926 53. Silverstein RL, Li W, Park YM, and Rahaman SO. Mechanisms of cell signaling by the
927 scavenger receptor CD36: implications in atherosclerosis and thrombosis. *Trans Am Clin*
928 *Climatol Assoc.* 2010;121(206-20).
- 929 54. Higaki Y, Hirshman MF, Fujii N, and Goodyear LJ. Nitric oxide increases glucose uptake
930 through a mechanism that is distinct from the insulin and contraction pathways in rat
931 skeletal muscle. *Diabetes.* 2001;50(2):241-7.
- 932 55. Pappas G, Wilkinson ML, and Gow AJ. Nitric oxide regulation of cellular metabolism:
933 Adaptive tuning of cellular energy. *Nitric Oxide.* 2023;131(8-17).
- 934 56. Dransfeld O, Rakatzi I, Sasson S, Gruzman A, Schmitt M, Haussinger D, and Eckel J.
935 Eicosanoids participate in the regulation of cardiac glucose transport by contribution to a
936 rearrangement of actin cytoskeletal elements. *Biochem J.* 2001;359(Pt 1):47-54.
- 937 57. Viswambharan H, Yuldasheva NY, Imrie H, Bridge K, Haywood NJ, Skromna A,
938 Hemmings KE, Clark ER, Gatenby VK, Cordell P, et al. Novel Paracrine Action of
939 Endothelium Enhances Glucose Uptake in Muscle and Fat. *Circ Res.* 2021;129(7):720-34.
- 940 58. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, and Masys DR.
941 Development of a large-scale de-identified DNA biobank to enable personalized medicine.
942 *Clin Pharmacol Ther.* 2008;84(3):362-9.
- 943 59. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO,
944 Marchini JL, McCarthy S, McVean GA, et al. A global reference for human genetic
945 variation. *Nature.* 2015;526(7571):68-74.
- 946 60. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E,
947 Glazer NL, Bouatia-Naji N, Gloyn AL, et al. New genetic loci implicated in fasting glucose
948 homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010;42(2):105-16.